The remaining 25% of HPT-JT patients may have abnormalities in CDC73 promoter regions, whole exon or gene deletions, mutations in unidentified genes, or epigenetic modifications [15]. Here, CDC73 is linked to Hyperparathyroidism-jaw tumor syndrome.